[go: up one dir, main page]

CR9864A - Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo - Google Patents

Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo

Info

Publication number
CR9864A
CR9864A CR9864A CR9864A CR9864A CR 9864 A CR9864 A CR 9864A CR 9864 A CR9864 A CR 9864A CR 9864 A CR9864 A CR 9864A CR 9864 A CR9864 A CR 9864A
Authority
CR
Costa Rica
Prior art keywords
oral administration
solid pharmaceutical
quick release
active principle
prophylaxis
Prior art date
Application number
CR9864A
Other languages
English (en)
Inventor
Klaus Benke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37852804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CR9864A publication Critical patent/CR9864A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invencion se refiere a formas de dosificacion farmaceutica solidas de administracion oral con liberacion del principio activo rapida, 5-cloro-N-({5S)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2- tiofenocarboxamida, que estan en forma amorfa y/o contienen una modificacion cristalina termodinamicamente metaestable con liberacion rapida de principio activo, asi como a procedimientos para su preparacion, su uso como medicamento, su uso para profilaxis, profilaxis secundaria y/o tratamiento de enfermedades, asi como su uso para la preparacion de un medicamento para la profilaxis, profilaxis secundaria y/o tratamiento de enfermedades.
CR9864A 2005-10-04 2008-04-03 Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo CR9864A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005047561A DE102005047561A1 (de) 2005-10-04 2005-10-04 Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
CR9864A true CR9864A (es) 2008-10-31

Family

ID=37852804

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9864A CR9864A (es) 2005-10-04 2008-04-03 Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo

Country Status (26)

Country Link
US (1) US8586082B2 (es)
EP (1) EP1957048A2 (es)
JP (1) JP5147703B2 (es)
KR (1) KR101445398B1 (es)
CN (1) CN101321517B (es)
AR (1) AR056564A1 (es)
AU (1) AU2006299192B2 (es)
BR (1) BRPI0616874A2 (es)
CA (1) CA2624306C (es)
CR (1) CR9864A (es)
CU (1) CU23808B7 (es)
DE (1) DE102005047561A1 (es)
DO (1) DOP2006000209A (es)
EC (1) ECSP088339A (es)
GT (1) GT200600445A (es)
IL (1) IL190618A0 (es)
MY (1) MY143351A (es)
NZ (1) NZ567094A (es)
PE (1) PE20070588A1 (es)
RU (1) RU2440119C2 (es)
SV (1) SV2009002857A (es)
TW (1) TWI389691B (es)
UA (1) UA90545C2 (es)
UY (1) UY29835A1 (es)
WO (1) WO2007039122A2 (es)
ZA (1) ZA200802873B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
JP2011527297A (ja) * 2008-07-08 2011-10-27 ラーツイオフアルム・ゲー・エム・ベー・ハー ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（３−オキソ−４−モルホリニル）−フェニル］−１，３−オキサゾリジン−５−イル｝−メチル）−２−チオフェンカルボキサミドを含む医薬組成物
EP2317980A2 (en) * 2008-08-11 2011-05-11 Ratiopharm GmbH Pharmaceutical compositions of rivaroxaban with modified release properties
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
PL2442799T5 (pl) 2009-06-18 2019-09-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Kompozycja farmaceutyczna w postaci stałej zawierająca rywaroksaban
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
EP2485715A1 (en) 2009-10-06 2012-08-15 Ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
EP2568968B1 (en) 2010-05-10 2017-07-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
SE1251371A1 (sv) 2010-05-10 2012-12-27 Euro Celtique Sa Farmaceutiska kompositioner innefattande hydromorfon och naloxon
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
US8906949B2 (en) * 2010-05-21 2014-12-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of zolmitriptan and process for preparing the same
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
DE102010063127A1 (de) 2010-12-15 2012-06-21 Bayer Schering Pharma Aktiengesellschaft Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20130064888A1 (en) 2011-08-08 2013-03-14 Roey Solomonovich Pharmaceutical formulations
EP2808011A1 (en) * 2013-05-29 2014-12-03 Sandoz Ag Process for the preparation of a pharmaceutical composition comprising Rivaroxaban
CN103550166A (zh) * 2013-10-31 2014-02-05 江苏阿尔法药业有限公司 一种利伐沙班口服微球制剂
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015124995A1 (en) 2014-02-19 2015-08-27 Aurobindo Pharma Ltd Solid dosage forms of rivaroxaban
KR101499867B1 (ko) * 2014-04-22 2015-03-06 에스케이케미칼주식회사 활성 성분 (i) 함유 조성물 및 이의 제조 방법
KR102333463B1 (ko) * 2014-07-02 2021-12-03 한미약품 주식회사 리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법
CN104666262B (zh) * 2015-02-03 2017-09-15 山东新时代药业有限公司 一种利伐沙班片
ES2992002T3 (es) * 2016-04-06 2024-12-05 Astellas Pharma Inc Moldeo tridimensional de elución rápida, filamento para moldeo tridimensional de elución rápida y material para moldeo tridimensional de elución rápida
EP3565532A4 (en) * 2017-01-04 2020-10-28 Bonayo Lifesciences Private Limited ORAL DISPERSIBLE FILM COMPOSITION
EP3796915A4 (en) 2018-11-16 2022-01-26 Santa Farma Ilaç Sanayi A.S. ORAL FORMULATIONS CONTAINING RIVAROXABAN
JP7305527B2 (ja) * 2018-11-30 2023-07-10 大原薬品工業株式会社 リバーロキサバンと嬌味剤を含有する固形製剤
US11073030B1 (en) * 2020-05-21 2021-07-27 Raytheon Technologies Corporation Airfoil attachment for gas turbine engines
JP7511596B2 (ja) * 2021-03-10 2024-07-05 日本ジェネリック株式会社 リバーロキサバン含有錠剤
GR1010231B (el) 2021-03-24 2022-05-10 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US629201A (en) * 1898-07-13 1899-07-18 Adolph Mueller Means for preventing sparking when and breaking electric circuits.
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4344934A (en) 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES533097A0 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
CA1317594C (en) 1987-10-21 1993-05-11 Chung-Ho Park Aminomethyloxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
US4977173A (en) 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
US5564571A (en) 1993-07-19 1996-10-15 Cembre S.P.A. Strip for electrical connectors
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
BR9607017A (pt) 1995-02-03 1997-10-28 Upjohn Co Composto e uso do mesmo
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2228647A1 (en) 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
DK1019385T3 (da) 1995-09-15 2004-05-24 Upjohn Co Aminoaryloxazolidinon-N-oxider
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
RU2220723C2 (ru) 1996-07-15 2004-01-10 Санкио Компани, Лимитед Средство и способ лечения или профилактики артериосклероза
JPH10175816A (ja) * 1996-12-18 1998-06-30 Toray Dow Corning Silicone Co Ltd 化粧品原料、化粧品、および化粧品の製造方法
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5935724A (en) 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
CN1138765C (zh) 1997-05-30 2004-02-18 法玛西雅厄普约翰美国公司 带有硫代羰基功能基的噁唑烷酮抗菌剂
AU729745B2 (en) 1997-07-11 2001-02-08 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
CN1154644C (zh) 1997-11-12 2004-06-23 法玛西雅厄普约翰美国公司 噁唑烷酮衍生物和药物组合物
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
AU764184B2 (en) 1998-01-23 2003-08-14 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
EA200000768A1 (ru) 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
ES2182521T3 (es) 1998-05-18 2003-03-01 Upjohn Co Mejoramiento de la actividad de agentes antibacterianos de oxazolidinona mediante derivados de arginina.
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
SK7572002A3 (en) 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN1413218A (zh) 1999-12-28 2003-04-23 味之素株式会社 天冬甜素衍生物的结晶
US6514529B2 (en) 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
EP1641437A4 (en) * 2003-07-09 2009-06-03 Chong Kun Dang Pharm Corp SOLID DISPERSION OF TACROLIMUS
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
JP2007517016A (ja) * 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1934208B1 (de) 2005-10-04 2011-03-23 Bayer Schering Pharma Aktiengesellschaft Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien

Also Published As

Publication number Publication date
ZA200802873B (en) 2009-09-30
JP2009510138A (ja) 2009-03-12
TWI389691B (zh) 2013-03-21
SV2009002857A (es) 2009-01-14
CA2624306A1 (en) 2007-04-12
CU20080052A7 (es) 2011-04-26
RU2440119C2 (ru) 2012-01-20
HK1127284A1 (en) 2009-09-25
JP5147703B2 (ja) 2013-02-20
CU23808B7 (es) 2012-04-15
CN101321517A (zh) 2008-12-10
AU2006299192B2 (en) 2012-04-19
DE102005047561A1 (de) 2007-04-05
DOP2006000209A (es) 2007-04-30
RU2008116831A (ru) 2009-11-10
IL190618A0 (en) 2008-11-03
WO2007039122A2 (de) 2007-04-12
AR056564A1 (es) 2007-10-10
BRPI0616874A2 (pt) 2011-07-05
US20100151011A1 (en) 2010-06-17
US8586082B2 (en) 2013-11-19
GT200600445A (es) 2007-05-08
PE20070588A1 (es) 2007-08-17
CN101321517B (zh) 2012-11-28
TW200803866A (en) 2008-01-16
ECSP088339A (es) 2008-06-30
UY29835A1 (es) 2007-05-31
EP1957048A2 (de) 2008-08-20
WO2007039122A3 (de) 2007-10-11
NZ567094A (en) 2011-05-27
AU2006299192A1 (en) 2007-04-12
UA90545C2 (ru) 2010-05-11
KR20080067638A (ko) 2008-07-21
KR101445398B1 (ko) 2014-09-26
CA2624306C (en) 2014-12-09
MY143351A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
CR9864A (es) Formas de presentacion farmaceutica solidas de administracion oral con liberacion rapida de principio activo
BRPI0519376A2 (pt) formas de administraÇço farmacÊuticas sàlidas, aplicÁveis por via oral, contendo rivaroxaban com liberaÇço modificada
ECSP066584A (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
AR109300A2 (es) Formas cristalinas del ácido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico
ECSP14033581A (es) Formas de administración farmacéuticas que comprenden 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)fenil]-1,3-oxazolidin-5-il}metil)-2-tiofencarboxamida
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
DK1987026T3 (da) Aminoacyl-prodrugderivater og lægemidler til behandling af thromboemboliske sygdomme
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
CO2020000292A2 (es) Preparación medicinal combinada para tratar infecciones virales
UY29305A1 (es) Formas de dosificación farmacéutica sólidas administrables por vía oral con liberación modificada
CU23673B7 (es) Formas de dosificacion farmacéutica sólidas administrables por vía oral con liberación modificada
NO20081982L (no) Faste, oralt administrerbare farmasoytiske doseringsformer med rask frigivelse av aktiv forbindelse
CL2012003685A1 (es) Kit farmaceutico que comprende una o mas unidades de envasado que comprenden 21 a 28 unidades de dosificacion activas diarias en que cada una comprende por lo menos 2 mg de drosperidona, sin estrogernos; uso del kit y de una composicion farmaceutica que comprende drosperidona para preparar un medicamento util como anticonceptivo.
UY28628A1 (es) Procedimiento para la preparación de una composición farmacéutica sólida administrable oralmente
DOP2004001034A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente que comprende 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida en forma hidrofilizada
DOP2005000265A (es) Forma de dosificacion farmaceutica solidas administrables por via oral con liberacion modificada.

Legal Events

Date Code Title Description
FC Refusal